Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), discusses the development process for the section of ADA guidelines that touches on chronic kidney disease (CKD) management in patients with diabetes.
Robert Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association (ADA), discusses how the ADA developed section 11 of its new guidelines, which focus on the management of chronic kidney disease in patients with diabetes.
In recent years, the ADA has taken a comprehensive approach, working with other professional societies on guidelines in cardiovascular and renal care. Is the new section 11 an outgrowth of those conversations?
The American Diabetes Association works with a number of other societies for various sections of our standards of care. What we are very careful about doing is the makeup of our professional practice committee that is the group of individuals that develop our standards of care. And what we do is we have a broad-scale multidisciplinary, multiple-professional group—so, different types of professionals and specialists. For example, for the kidney section, we had nephrologists on the group that helped to guide these standards along with the discussion in the broader professional practice committee.